Paris-based AI HealthCare startup Theremia has attracted €3M to allow individualized medication to mitigate side effects and enhance outcomes in Europe.
Theremia has secured €3M in a seed funding round from Eurazeo, Salica Investments, Entrepreneur First, and BPIFrance. This funding will enable Theremia to scale up a personalized medicine platform by expanding its scientific talent as well as establishing symbiotic relationships with various medical institutions throughout Europe.
Individualized Treatment with Advanced AI HealthCare Solution:
Theremia’s technology-driven program works on a principle that offers solutions based on the patient’s characteristics and not from general solutions that may not suit him or her. Theremia therefore seeks to decrease those side effects by making aspects of treatment, such as dosage and frequency, more patient-specific: which should increase treatment compliance. Numerical reports show that around 60% of patients discontinue medications because of side effects or lack of improvement—a situation that Theremia refuses to let continue.
Related Content: Mental Health AI Startup clare&me Raises €3.7M Funding
It synthesizes its treatment pathways with HealthCare givers particularly those in neurology and psychiatry specialties. Such collaborations make certain that the models used on the platform are not only academically valid but are suitable for the high degree of intricacy of certain states of health, making the platform more accurate.
Using RWD in Supporting Drug Development:
Originally, Theremia’s platform offered drug developers tangible information on its intended effectiveness within real-life applications, specifically for treating specified patient segments. This data approach fits the concept of a value-based HealthCare environment where the treatments are measured, not only on the overall effectiveness but on the patient’s cases.
Chaired by Academic of Public Health and Neuropsychologist:
The Theremia team consists of public health specialist Iris Maréchal, neuroscientist Chloé Geoffroy, and numerous other professionals involved in the scientific and technological sectors, focused on enhancing and developing the company’s PM platform. Holding this diverse expertise, Theremia is ready to direct the further development of more individualized approaches to the AI HealthCare sector in Europe.
